Federal Register / Vol. 69, No. 248 / Tuesday, December 28, 2004 / Notices 77759

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets of commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel SBIR Topic 

206: Methods of Innovative Pharmaceutical 

Manufacturing & Quality Assurance. 

Date: February 16, 2005. 

Time: 12 p.m. to 4:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6130 

Executive Blvd., Rockville, MD 20852, 

(Telephone conference call). 

Contact Person: Kenneth L. Bielat, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, Room 7147, Bethesda, 

MD 20892, (301) 496–7576, 

bielatk@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS.)

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–28312 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel. RFP SBIR 

TOPIC 207—Synthesis Modules of Radio 

Pharmaceutical Production. 

Date: February 23, 2005. 

Time: 12 p.m. to 4:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6130 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Kenneth L Bielat, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, Room 7147, Bethesda, 

MD 20892, (301) 496–7576, 

bielatk@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS.)

Dated: December 20, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–28314 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel Cancer 

Prevention, Control, Behavioral and 

Population Sciences Career Development 

Award (K07) PAR–04–055. 

Date: January 27, 2005. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Robert Bird, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, National 

Cancer Institute, National Institutes of 

Health, 6116 Executive Blvd., MSC 8328, 

Room 8113, Bethesda, MD 20892–8328, (301) 

496–7978, birdr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS.)

Dated: December 20, 2004

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–28319 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine, Notice of 

Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. appendix 2), notice 

is hereby given of the National Advisory 

Council for Complementary and 

Alternative Medicine (NACCAM) 

meeting. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such a patentable material, and personal 

information concerning individuals 

associated with the grant applications 

and/or contract proposals, the

77760 Federal Register / Vol. 69, No. 248 / Tuesday, December 28, 2004 / Notices 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy.

Name of Committee: National Advisory 

Council for Complementary and Alternative 

Medicine. 

Date: January 28, 2005. 

Closed: 8:30 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Open: 12:30 p.m. to adjournment. 

Agenda: The agenda includes Opening 

Remarks by Director, NCCAM, NCCAM’s 

second five-year Strategic Plan and other 

business of the Council. 

Place: Neuroscience Conference Center, 

6001 Executive Boulevard, Conference 

Rooms C and D, Rockville, MD 20892. 

Contact Person: Jane F. Kinsel, PhD., 

M.B.A., Executive Secretary, National Center 

for Complementary and Alternative 

Medicine, National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892, 301–496–6701.

The public comments session is 

scheduled from 4:30–5 p.m., but could 

change depending on the actual time 

spent on each agenda item. Each 

speaker will be permitted 5 minutes for 

their presentation. Interested 

individuals and representatives of 

organizations are requested to notify Dr. 

Jane Kinsel, National Center for 

Complementary and Alternative 

Medicine, NIH, 6707 Democracy 

Boulevard, Suite 401, Bethesda, 

Maryland, 20892, 301–496–6701, Fax: 

301–480–0087. Letters of intent to 

present comments, along with a brief 

description of the organization 

represented, should be received no later 

than 5 p.m. on January 20, 2005. Only 

one representative of an organization 

may present oral comments. Any person 

attending the meeting who does not 

request an opportunity to speak in 

advance of the meeting may be 

considered for oral presentation, if time 

permits, and at the discretion of the 

Chairperson. In addition, written 

comments may be submitted to Dr. Jane 

Kinsel at the address listed above up to 

ten calendar days (February 9, 2005) 

following the meeting. 

Copies of the meeting agenda and the 

roster of members will be furnished 

upon request by contacting Dr. Jane 

Kinsel, Executive Secretary, NACCAM, 

National Institutes of Health, 6707 

Democracy Boulevard, Suite 401, 

Bethesda, Maryland 20892, 301–496–

6701, Fax 301–480–0087, or via e-mail 

at naccames@mail.nih.gov.

Dated: December 20, 2004. 

Laverne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy, NIH.

[FR Doc. 04–28309 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Review of Heart Study Applications. 

Date: January 6, 2005. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone conference call). 

Contact Person: Valerie L. Prenger, PhD, 

Health Scientist Administrator, Review 

Branch, Room 7194, Division of Extramural 

Affairs, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 

Bethesda, MD 20892–7924, (301) 435–0288. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS.)

Dated: December 20, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–28310 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Genetic Pathway to SLE. 

Date: January 12, 2005. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Room 3143, Bethesda, MD 20817; (Telephone 

Conference Call). 

Contact Person: Kenneth E. Santora, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/

NIAID/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892–7616; 301–496–

2550; ks216i@nih.gov.

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, SLE Pathogenesis. 

Date: January 13, 2005. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Room 3265, Bethesda, MD 20817; (Telephone 

Conference Call). 

Contact Person: Kenneth E. Santora, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/

NIAID/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892–7616; 301–496–

2550; ks216i@nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS.)

Dated: December 20, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–28306 Filed 12–27–04; 8:45 am] 

BILLING CODE 4140–01–M